Effect of Hepatic Impairment on <scp>OATP1B</scp> Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs

  • Jian Lin
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA
  • Emi Kimoto
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA
  • Shinji Yamazaki
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc. San Diego California USA
  • Manoli Vourvahis
    Clinical Pharmacology, Global Product Development Pfizer Inc. New York New York USA
  • Arthur Bergman
    Clinical Pharmacology, Early Clinical Development Pfizer Inc. Cambridge Massachusetts USA
  • A. David Rodrigues
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA
  • Chester Costales
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA
  • Rui Li
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc. Cambridge Massachusetts USA
  • Manthena V. S. Varma
    Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA

書誌事項

公開日
2023-01-15
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1002/cpt.2829
公開者
Wiley

この論文をさがす

説明

<jats:p>Hepatic impairment (HI) is known to modulate drug disposition and may lead to elevated plasma exposure. The aim of this study was to quantitate the <jats:italic>in vivo</jats:italic> OATP1B‐mediated hepatic uptake activity in populations with varying degrees of HI. First, we measured baseline levels of plasma coproporphyrin‐I, an endogenous OATP1B biomarker, in an open‐label, parallel cohort study in adult subjects with normal liver function and mild, moderate, and severe HI (<jats:italic>n</jats:italic> = 24, 6/cohort). The geometric mean plasma concentrations of coproporphyrin‐I were 1.66‐fold, 2.81‐fold (<jats:italic>P</jats:italic> < 0.05), and 7.78‐fold (<jats:italic>P</jats:italic> < 0.0001) higher in mild, moderate, and severe impairment than those healthy controls. Second, we developed a dataset of 21 OATP1B substrate drugs with HI data extracted from literature. Median disease‐to‐healthy plasma area under the curve (AUC) ratios for substrate drugs were ~ 1.4, 3.0, and 6.4 for mild, moderate, and severe HI, respectively. Additionally, significant linear relationship was noted between AUC ratios of substrate drugs without and with co‐administration of rifampin, a prototypic OATP1B inhibitor, and AUC ratios in moderate (<jats:italic>P</jats:italic> < 0.01) and severe (<jats:italic>P</jats:italic> < 0.001) HI. Third, a physiologically‐based pharmacokinetic model analysis was conducted with 10 substrate drugs following estimation of relative OATP1B functional activity in virtual disease population models using coproporphyrin‐I data and verification of substrate models with rifampin drug–drug interaction data. This approach adequately predicted plasma AUC change particularly in moderate (9 of 10 within 2‐fold) and severe (5 of 5 within 2‐fold) HI. Collective findings indicate progressive reduction, by as much as 90–92%, in OATP1B activity in the HI population.</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ